Come November, we will know how Day One Biopharmaceuticals Inc.'s (DAWN) first and only marketed drug, Ojemda, fared in its first full quarter on the market.
Ojemda was granted accelerated approval by the FDA for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation on Apr.23, 2024.
Pediatric low-grade glioma (pLGG) is the most common type of brain tumor in children. Up to 75% of pLGGs have a BRAF alteration - of those about 80% are BRAF fusions and roughly 20% are BRAF V600 mutations. Despite surgery playing a significant role in treatment, the vast majority of patients still require systemic therapy. Due to the high rate of disease recurrence, most patients will undergo multiple lines of systemic therapy over the course of their disease.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.